Guardant Health (GH) Financials

$45.16 +1.45 (+3.32%)

As of 04/14/2025 04:00 PM Eastern

Annual Income Statements for Guardant Health

This table shows Guardant Health's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Income / (Loss) Attributable to Common Shareholders	-46	-89	-85	-76	-254	-406	-655	-479	-436
Consolidated Net Income / (Loss)	-46	-83	-84	-68	-246	-385	-655	-479	-436
Net Income / (Loss) Continuing Operations	-46	-83	-84	-68	-246	-385	-655	-479	-436
Total Pre-Tax Income	-46	-83	-84	-70	-246	-384	-653	-479	-435
Total Operating Income	-44	-77	-93	-82	-255	-411	-544	-565	-444
Total Gross Profit	25	47	87	206	269	361	441	542	710
Total Revenue	25	50	91	214	287	374	450	564	739
Operating Revenue	25	50	91	214	287	374	450	564	739
Total Cost of Revenue	0.06	2.74	3.36	8.47	18	13	8.13	22	29
Operating Cost of Revenue	0.06	2.74	3.36	8.47	18	13	8.13	22	29
Total Operating Expenses	69	124	180	288	524	772	986	1,107	1,153
Selling, General & Admin Expense	9.92	37	36	61	193	207	164	239	180
Marketing Expense	26	32	53	78	107	192	300	295	365
Research & Development Expense	11	26	51	86	150	263	374	367	348
Other Operating Expenses / (Income)	22	29	40	62	75	110	148	206	261
Total Other Income / (Expense), net	-2.29	-6.60	8.72	13	9.05	27	-106	89	11
Interest Expense	3.02	7.78	1.25	1.18	4.77	2.58	100	0.00	0.00
Interest & Investment Income	0.73	2.23	5.27	14	10	3.93	6.07	35	54
Other Income / (Expense), net	-0.00	-1.06	4.70	0.09	3.64	25	-13	53	-43
Income Tax Expense	0.01	0.01	0.04	-1.87	0.38	0.30	1.14	0.69	1.28
Basic Earnings per Share	($3.53)	($7.07)	($2.80)	($0.84)	($2.60)	($4.00)	($6.41)	($4.28)	($3.56)
Weighted Average Basic Shares Outstanding	13.05M	12.58M	30.40M	90.60M	97.50M	101.31M	102.18M	111.99M	122.75M
Diluted Earnings per Share	($3.53)	($7.07)	($2.80)	($0.84)	($2.60)	($4.00)	($6.41)	($4.28)	($3.56)
Weighted Average Diluted Shares Outstanding	13.05M	12.58M	30.40M	90.60M	97.50M	101.31M	102.18M	111.99M	122.75M
Weighted Average Basic & Diluted Shares Outstanding	13.05M	12.58M	30.40M	90.60M	97.50M	101.87M	102.66M	121.71M	123.42M

This table shows Guardant Health's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Income / (Loss) Attributable to Common Shareholders	-162	-140	-134	-73	-86	-187	-115	-103	-108	-111
Consolidated Net Income / (Loss)	-162	-140	-134	-73	-86	-187	-115	-103	-108	-111
Net Income / (Loss) Continuing Operations	-162	-140	-134	-73	-86	-187	-115	-103	-108	-111
Total Pre-Tax Income	-162	-139	-133	-72	-86	-188	-115	-102	-108	-110
Total Operating Income	-145	-146	-134	-120	-114	-198	-100	-101	-117	-126
Total Gross Profit	116	123	121	133	139	150	163	171	183	194
Total Revenue	117	127	129	137	143	155	168	177	191	202
Operating Revenue	117	127	129	137	143	155	168	177	191	202
Total Cost of Revenue	1.06	3.42	7.97	4.49	3.97	5.10	5.99	6.71	8.39	8.13
Operating Cost of Revenue	1.06	3.42	7.97	4.49	3.97	5.10	5.99	6.71	8.39	8.13
Total Operating Expenses	261	270	255	252	253	347	262	271	300	320
Selling, General & Admin Expense	41	38	40	42	36	121	39	40	49	52
Marketing Expense	80	81	76	71	69	79	80	82	98	105
Research & Development Expense	100	107	93	90	94	90	84	83	87	94
Other Operating Expenses / (Income)	39	44	45	49	54	57	59	66	66	69
Total Other Income / (Expense), net	-17	9.36	0.76	48	29	11	-15	-1.23	10	17
Interest & Investment Income	1.75	2.15	3.06	6.73	12	14	15	14	13	12
Other Income / (Expense), net	-18	5.28	-1.65	41	17	-3.32	-29	-15	-3.01	4.67
Income Tax Expense	0.12	0.60	0.24	0.50	0.49	-0.54	0.41	0.13	0.03	0.72
Basic Earnings per Share	($1.58)	($1.37)	($1.30)	($0.67)	($0.73)	($1.58)	($0.94)	($0.84)	($0.88)	($0.90)
Weighted Average Basic Shares Outstanding	102.29M	102.18M	102.66M	108.81M	117.74M	111.99M	121.71M	122.45M	123.05M	122.75M
Diluted Earnings per Share	($1.58)	($1.37)	($1.30)	($0.67)	($0.73)	($1.58)	($0.94)	($0.84)	($0.88)	($0.90)
Weighted Average Diluted Shares Outstanding	102.29M	102.18M	102.66M	108.81M	117.74M	111.99M	121.71M	122.45M	123.05M	122.75M
Weighted Average Basic & Diluted Shares Outstanding	102.44M	102.66M	102.76M	117.69M	117.99M	121.71M	122.37M	123.02M	123.55M	123.42M

This table details how cash moves in and out of Guardant Health's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Net Change in Cash & Equivalents	29	39	68	2.68	690	-341	-350	992	-504
Net Cash From Operating Activities	-37	-72	-72	-47	-104	-209	-309	-325	-240
Net Cash From Continuing Operating Activities	-37	-72	-72	-47	-104	-209	-309	-325	-240
Net Income / (Loss) Continuing Operations	-46	-83	-84	-68	-246	-385	-655	-479	-436
Consolidated Net Income / (Loss)	-46	-83	-84	-68	-246	-385	-655	-479	-436
Depreciation Expense	3.69	5.21	7.14	11	16	22	36	43	42
Amortization Expense	0.29	0.36	-0.41	-2.31	8.75	15	7.16	-11	-4.19
Non-Cash Adjustments To Reconcile Net Income	3.00	10	6.48	18	159	190	216	37	182
Changes in Operating Assets and Liabilities, net	2.45	-4.99	-1.13	-6.83	-42	-52	86	85	-24
Net Cash From Investing Activities	26	-170	-153	-318	-617	-63	150	840	-261
Net Cash From Continuing Investing Activities	26	-170	-153	-318	-617	-63	150	840	-261
Purchase of Property, Plant & Equipment	-1.77	-6.68	-20	-19	-36	-75	-77	-20	-35
Purchase of Investments	-341	-237	-287	-614	-1,126	-901	-304	-635	-307
Sale and/or Maturity of Investments	369	75	155	325	563	952	555	1,496	89
Other Investing Activities, net	-	-2.30	0.00	-0.07	0.00	-39	-24	-	-7.50
Net Cash From Financing Activities	40	282	293	367	1,410	-67	-189	477	-1.00
Net Cash From Continuing Financing Activities	40	282	293	367	1,410	-67	-189	477	-1.00
Repayment of Debt	-	-0.24	-	0.00	0.00	-0.93	-1.14	6.03	-0.15
Repurchase of Common Equity	-0.10	-7.22	-4.56	-0.72	-1.13	0.00	0.00	-21	0.00
Issuance of Common Equity	0.19	0.00	295	357	363	9.75	9.32	503	12
Other Financing Activities, net	-0.11	-25	2.71	11	-84	-76	-197	-11	-13
Effect of Exchange Rate Changes	-	-	-	0.08	0.46	-1.69	-1.60	-0.91	-1.77
Cash Income Taxes Paid	0.01	0.03	0.10	0.30	0.33	0.39	1.33	1.97	1.01

This table details how cash moves in and out of Guardant Health's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Net Change in Cash & Equivalents	-57	-17	82	47	186	676	-4.43	-94	-347	-59
Net Cash From Operating Activities	-78	-91	-74	-94	-78	-79	-30	-94	-51	-65
Net Cash From Continuing Operating Activities	-78	-91	-74	-94	-78	-79	-30	-94	-51	-65
Net Income / (Loss) Continuing Operations	-162	-140	-134	-73	-86	-187	-115	-103	-108	-111
Consolidated Net Income / (Loss)	-162	-140	-134	-73	-86	-187	-115	-103	-108	-111
Depreciation Expense	9.81	10	10	11	11	11	11	11	11	10
Amortization Expense	0.21	1.87	-0.37	-1.43	-7.18	-2.00	0.76	0.64	-2.28	-3.31
Non-Cash Adjustments To Reconcile Net Income	40	18	23	-18	5.10	26	57	42	51	32
Changes in Operating Assets and Liabilities, net	34	19	26	-13	-0.64	73	17	-45	-2.87	7.26
Net Cash From Investing Activities	41	71	157	-241	261	663	28	-5.08	-295	11
Net Cash From Continuing Investing Activities	41	71	157	-241	261	663	28	-5.08	-295	11
Purchase of Property, Plant & Equipment	-22	-10	-7.52	-6.51	-2.37	-4.08	-6.93	-5.08	-4.20	-19
Sale and/or Maturity of Investments	63	157	228	265	336	668	35	-	19	34
Other Investing Activities, net	-	-11	-	-	-4.37	-	-	-	-2.50	-5.00
Net Cash From Financing Activities	-19	2.32	-0.85	384	3.81	91	-1.07	5.90	-2.89	-2.94
Net Cash From Continuing Financing Activities	-19	2.32	-0.85	384	3.81	91	-1.07	5.90	-2.89	-2.94
Repayment of Debt	-	-0.02	-0.02	-0.02	5.95	0.12	0.26	-0.44	-0.03	0.06
Issuance of Common Equity	-	3.57	-	-	-	94	-	-	-	4.51
Other Financing Activities, net	-18	-1.24	-0.84	-4.05	-2.93	-2.97	-1.33	-0.88	-2.85	-7.50
Effect of Exchange Rate Changes	-0.53	1.14	-0.16	-1.25	-0.53	1.03	-1.14	-0.84	1.90	-1.70

This table presents Guardant Health's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2017	2018	2019	2020	2021	2022	2023	2024
Total Assets	343	587	963	2,272	2,204	1,610	1,786	1,486
Total Current Assets	243	469	597	1,888	1,114	1,192	1,347	1,055
Cash & Equivalents	72	141	143	833	492	142	1,134	526
Short-Term Investments	149	278	380	962	441	870	35	314
Accounts Receivable	13	36	48	53	98	97	89	110
Inventories, net	7.29	9.14	15	23	31	52	62	71
Prepaid Expenses	1.54	5.20	11	17	53	32	28	34
Plant, Property, & Equipment, net	16	31	44	63	124	168	145	137
Total Noncurrent Assets	84	87	322	321	966	250	294	294
Goodwill	-	0.00	3.29	3.29	3.29	3.29	3.29	3.29
Intangible Assets	8.74	7.80	8.52	16	14	12	8.98	6.76
Other Noncurrent Operating Assets	1.97	2.05	41	55	250	235	282	284
Total Liabilities & Shareholders' Equity	343	587	963	2,272	2,204	1,610	1,786	1,486
Total Liabilities	34	62	115	916	1,559	1,550	1,628	1,625
Total Current Liabilities	20	47	73	67	195	193	206	226
Accounts Payable	5.00	11	16	7.34	105	176	52	39
Accrued Expenses	6.41	7.18	26	23	-	-	63	68
Current Deferred Revenue	3.11	16	12	8.55	11	17	18	35
Current Employee Benefit Liabilities	4.91	13	19	28	-	-	73	83
Total Noncurrent Liabilities	15	16	42	849	1,365	1,357	1,422	1,400
Long-Term Debt	-	-	0.00	806	1,135	1,137	1,140	1,143
Other Noncurrent Operating Liabilities	7.71	7.66	42	43	230	219	282	257
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	309	483	798	1,298	645	60	159	-140
Total Preferred & Common Equity	309	483	798	1,298	645	60	159	-140
Preferred Stock	500	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	-191	483	798	1,298	645	60	159	-140
Common Stock	4.90	764	1,150	1,902	1,658	1,742	2,304	2,444
Retained Earnings	-196	-281	-353	-607	-1,008	-1,662	-2,142	-2,578
Accumulated Other Comprehensive Income / (Loss)	-0.53	-0.08	1.11	2.70	-4.76	-20	-3.68	-5.20

This table presents Guardant Health's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2022	Q1 2023	Q2 2023	Q3 2023	Q1 2024	Q2 2024	Q3 2024
Total Assets	1,702	1,512	1,840	1,797	1,705	1,609	1,539
Total Current Assets	1,131	1,104	1,398	1,347	1,309	1,290	1,227
Cash & Equivalents	158	224	271	457	1,129	1,035	688
Restricted Cash	-	-	-	-	-	0.00	0.00
Short-Term Investments	800	713	954	697	0.00	0.00	311
Accounts Receivable	86	87	86	89	85	101	88
Inventories, net	63	46	61	77	63	67	72
Prepaid Expenses	24	34	26	26	32	87	67
Plant, Property, & Equipment, net	168	163	156	148	138	132	125
Total Noncurrent Assets	403	244	287	303	258	187	187
Goodwill	3.29	3.29	3.29	3.29	3.29	3.29	3.29
Intangible Assets	12	11	10	9.67	8.29	7.74	7.25
Other Noncurrent Operating Assets	230	230	273	290	246	176	176
Total Liabilities & Shareholders' Equity	1,702	1,512	1,840	1,797	1,705	1,609	1,539
Total Liabilities	1,535	1,556	1,547	1,569	1,636	1,611	1,599
Total Current Liabilities	175	204	201	227	220	202	197
Accounts Payable	41	191	189	205	38	42	15
Accrued Expenses	63	-	-	-	67	71	72
Current Deferred Revenue	13	14	12	21	23	29	30
Current Employee Benefit Liabilities	57	-	-	-	93	59	81
Total Noncurrent Liabilities	1,360	1,352	1,346	1,342	1,416	1,409	1,401
Long-Term Debt	1,137	1,138	1,139	1,139	1,141	1,141	1,142
Other Noncurrent Operating Liabilities	223	214	208	203	276	268	260
Commitments & Contingencies	-	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	167	-45	293	228	68	-1.61	-60
Total Preferred & Common Equity	167	-45	293	228	68	-1.61	-60
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	167	-45	293	228	68	-1.61	-60
Common Stock	1,716	1,764	2,170	2,189	2,330	2,364	2,410
Retained Earnings	-1,522	-1,796	-1,869	-1,955	-2,257	-2,359	-2,467
Accumulated Other Comprehensive Income / (Loss)	-27	-12	-8.47	-5.68	-4.80	-5.64	-3.28

This table displays calculated financial ratios and metrics derived from Guardant Health's official financial filings.

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024
Growth Metrics	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	97.40%	81.85%	136.52%	33.75%	30.32%	20.31%	25.45%	31.04%
EBITDA Growth	0.00%	-80.86%	-13.05%	10.22%	-209.50%	-53.70%	-47.65%	6.69%	6.60%
EBIT Growth	0.00%	-77.14%	-13.61%	6.75%	-205.42%	-53.53%	-44.41%	8.19%	4.96%
NOPAT Growth	0.00%	-74.73%	-21.32%	11.37%	-209.51%	-61.21%	-32.45%	-3.74%	21.45%
Net Income Growth	0.00%	-80.37%	-1.25%	19.48%	-262.98%	-56.23%	-70.12%	26.76%	8.98%
EPS Growth	0.00%	-100.28%	60.40%	70.00%	-209.52%	-53.85%	-60.25%	33.23%	16.82%
Operating Cash Flow Growth	0.00%	-96.77%	0.07%	34.70%	-120.49%	-101.12%	-48.06%	-5.01%	26.19%
Free Cash Flow Firm Growth	0.00%	0.00%	-15.34%	-8.68%	-183.12%	-30.47%	-32.25%	18.97%	-1.31%
Invested Capital Growth	0.00%	0.00%	93.51%	98.42%	113.46%	23.78%	25.02%	-30.23%	25.31%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	16.29%	5.68%	8.66%	4.36%	5.26%	6.75%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	3.30%	-32.21%	4.38%	-14.87%	-15.16%	14.80%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	1.35%	-34.02%	4.37%	-14.02%	-13.28%	14.06%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	1.70%	-34.36%	-1.74%	-9.65%	-10.01%	13.89%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	4.45%	-40.45%	5.11%	-11.52%	-10.90%	14.84%
EPS Q/Q Growth	0.00%	0.00%	0.00%	-156.76%	-36.13%	1.72%	-8.09%	-5.16%	16.04%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	-13.43%	-8.78%	-38.48%	-9.29%	-4.65%	3.57%	5.59%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	-34.55%	13.52%	-13.24%	11.59%	-48.97%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	54.88%	43.68%	-10.65%	-1.26%	-38.90%	96.92%
Profitability Metrics	-	-	-	-	-	-	-	-	-
Gross Margin	99.77%	94.51%	96.29%	96.05%	93.80%	96.65%	98.19%	96.18%	96.05%
EBITDA Margin	-157.90%	-144.67%	-89.93%	-34.14%	-78.99%	-93.17%	-114.35%	-85.05%	-60.62%
Operating Margin	-173.66%	-153.71%	-102.54%	-38.42%	-88.92%	-110.00%	-121.10%	-100.14%	-60.03%
EBIT Margin	-173.66%	-155.83%	-97.35%	-38.38%	-87.65%	-103.26%	-123.94%	-90.71%	-65.79%
Profit (Net Income) Margin	-182.74%	-166.97%	-92.97%	-31.65%	-85.89%	-102.98%	-145.61%	-85.02%	-59.05%
Tax Burden Percent	100.01%	100.01%	100.05%	97.32%	100.15%	100.08%	100.17%	100.14%	100.30%
Interest Burden Percent	105.21%	107.14%	95.45%	84.74%	97.85%	99.65%	117.28%	93.59%	89.49%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	-730.09%	-301.77%	-135.93%	-201.86%	-213.54%	-227.24%	-249.91%	-212.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	-709.95%	-296.91%	-134.35%	-195.17%	-202.33%	-79.31%	-422.53%	-303.90%
Return on Net Nonoperating Assets (RNNOA)	0.00%	676.15%	281.55%	126.05%	179.51%	175.08%	41.59%	-188.21%	-4,372.47%
Return on Equity (ROE)	0.00%	-53.93%	-20.22%	-9.88%	-22.35%	-38.47%	-185.65%	-438.13%	-4,584.47%
Cash Return on Invested Capital (CROIC)	0.00%	-930.09%	-365.48%	-201.89%	-274.26%	-234.80%	-249.48%	-214.31%	-234.47%
Operating Return on Assets (OROA)	0.00%	-22.65%	-18.97%	-10.62%	-15.54%	-17.24%	-29.21%	-30.12%	-29.72%
Return on Assets (ROA)	0.00%	-24.27%	-18.11%	-8.76%	-15.23%	-17.19%	-34.32%	-28.23%	-26.67%
Return on Common Equity (ROCE)	0.00%	33.44%	-7.08%	-9.23%	-21.27%	-37.37%	-185.65%	-438.13%	-4,584.47%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-26.97%	-17.44%	-8.50%	-18.97%	-59.65%	-1,087.72%	-302.14%	312.48%
Net Operating Profit after Tax (NOPAT)	-31	-54	-65	-58	-178	-288	-381	-395	-311
NOPAT Margin	-121.56%	-107.60%	-71.78%	-26.90%	-62.24%	-77.00%	-84.77%	-70.10%	-42.02%
Net Nonoperating Expense Percent (NNEP)	0.00%	-20.14%	-4.86%	-1.58%	-6.69%	-11.21%	-147.93%	172.61%	91.90%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-	-	-	-31.82%	-30.44%	-30.96%
Cost of Revenue to Revenue	0.23%	5.49%	3.71%	3.95%	6.20%	3.35%	1.81%	3.82%	3.95%
SG&A Expenses to Revenue	39.29%	73.79%	39.93%	28.64%	67.23%	55.30%	36.47%	42.42%	24.37%
R&D to Revenue	43.01%	51.29%	55.95%	40.25%	52.27%	70.45%	83.15%	65.11%	47.06%
Operating Expenses to Revenue	273.42%	248.22%	198.83%	134.48%	182.72%	206.65%	219.29%	196.32%	156.07%
Earnings before Interest and Taxes (EBIT)	-44	-78	-88	-82	-251	-386	-557	-512	-486
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-40	-72	-82	-73	-226	-348	-514	-480	-448
Valuation Ratios	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	6.67	9.19	9.92	15.76	46.30	20.11	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	6.78	9.33	10.07	16.20	61.69	21.80	0.00
Price to Revenue (P/Rev)	9.41	4.77	35.56	34.23	44.94	27.21	6.20	5.66	5.11
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	30.19	97.40	116.93	97.22	64.89	15.63	24.33	25.03
Enterprise Value to Revenue (EV/Rev)	0.00	8.90	30.55	30.77	40.83	25.88	6.48	5.61	5.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.59	1.76	18.90	7.18	-8.18
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.59	1.76	18.90	7.18	-8.18
Financial Leverage	0.00	-0.95	-0.95	-0.94	-0.92	-0.87	-0.52	0.45	14.39
Leverage Ratio	0.00	1.11	1.12	1.13	1.47	2.24	5.41	15.52	171.88
Compound Leverage Factor	0.00	1.19	1.07	0.96	1.44	2.23	6.34	14.52	153.81
Debt to Total Capital	0.00%	0.21%	0.00%	0.00%	37.30%	63.76%	94.97%	87.78%	113.92%
Short-Term Debt to Total Capital	0.00%	0.06%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.15%	0.00%	0.00%	37.30%	63.76%	94.97%	87.78%	113.92%
Preferred Equity to Total Capital	0.00%	161.67%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	7.96%	5.85%	2.64%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-61.88%	92.04%	94.15%	60.06%	36.24%	5.03%	12.22%	-13.92%
Debt to EBITDA	0.00	-0.01	0.00	0.00	-3.56	-3.26	-2.21	-2.38	-2.55
Net Debt to EBITDA	0.00	4.08	0.00	0.00	5.45	1.42	-0.25	0.06	-0.68
Long-Term Debt to EBITDA	0.00	-0.01	0.00	0.00	-3.56	-3.26	-2.21	-2.38	-2.55
Debt to NOPAT	0.00	-0.01	0.00	0.00	-4.52	-3.94	-2.98	-2.88	-3.68
Net Debt to NOPAT	0.00	5.48	0.00	0.00	6.92	1.72	-0.33	0.07	-0.97
Long-Term Debt to NOPAT	0.00	-0.01	0.00	0.00	-4.52	-3.94	-2.98	-2.88	-3.68
Altman Z-Score	0.00	3.53	30.82	38.52	8.79	3.36	-0.49	-0.36	-0.95
Noncontrolling Interest Sharing Ratio	0.00%	162.01%	65.00%	6.66%	4.84%	2.85%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-
Current Ratio	0.00	12.38	9.99	8.21	28.27	5.72	6.17	6.54	4.68
Quick Ratio	0.00	11.93	9.69	7.85	27.66	5.29	5.74	6.11	4.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-68	-79	-86	-242	-316	-418	-339	-343
Operating Cash Flow to CapEx	-2,078.71%	-1,081.20%	-357.30%	-251.82%	-287.31%	-278.56%	-399.51%	-1,586.33%	-683.65%
Free Cash Flow to Firm to Interest Expense	0.00	-8.78	-62.99	-72.51	-50.87	-122.75	-4.19	0.00	0.00
Operating Cash Flow to Interest Expense	-12.16	-9.29	-57.70	-39.91	-21.81	-81.11	-3.10	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-12.75	-10.15	-73.85	-55.76	-29.40	-110.23	-3.88	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-
Asset Turnover	0.00	0.15	0.19	0.28	0.18	0.17	0.24	0.33	0.45
Accounts Receivable Turnover	0.00	3.90	3.74	5.12	5.66	4.95	4.61	6.06	7.43
Inventory Turnover	0.00	0.38	0.41	0.70	0.94	0.47	0.20	0.38	0.44
Fixed Asset Turnover	0.00	3.11	3.85	5.74	5.39	3.99	3.08	3.60	5.24
Accounts Payable Turnover	0.00	0.55	0.43	0.63	1.51	0.22	0.06	0.19	0.65
Days Sales Outstanding (DSO)	0.00	93.64	97.61	71.23	64.47	73.73	79.13	60.20	49.15
Days Inventory Outstanding (DIO)	0.00	972.49	890.96	524.26	389.29	778.50	1,847.73	962.75	830.93
Days Payable Outstanding (DPO)	0.00	667.01	848.48	578.63	241.78	1,643.33	6,314.91	1,929.44	563.98
Cash Conversion Cycle (CCC)	0.00	399.12	140.09	16.86	211.98	-791.11	-4,388.06	-906.49	316.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-
Invested Capital	0.00	15	28	56	120	149	186	130	163
Invested Capital Turnover	0.00	6.79	4.20	5.05	3.24	2.77	2.68	3.57	5.05
Increase / (Decrease) in Invested Capital	0.00	15	14	28	64	29	37	-56	33
Enterprise Value (EV)	0.00	444	2,769	6,596	11,706	9,672	2,912	3,163	4,077
Market Capitalization	238	238	3,223	7,338	12,884	10,168	2,786	3,192	3,775
Book Value per Share	$0.00	($15.21)	$5.63	$8.50	$12.99	$6.35	$0.59	$1.34	($1.13)
Tangible Book Value per Share	$0.00	($15.90)	$5.54	$8.38	$12.79	$6.17	$0.44	$1.24	($1.21)
Total Capital	0.00	309	525	848	2,162	1,780	1,198	1,299	1,003
Total Debt	0.00	0.66	0.00	0.00	806	1,135	1,137	1,140	1,143
Total Long-Term Debt	0.00	0.46	0.00	0.00	806	1,135	1,137	1,140	1,143
Net Debt	0.00	-294	-497	-792	-1,235	-496	126	-29	303
Capital Expenditures (CapEx)	1.77	6.68	20	19	36	75	77	20	35
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	2.19	3.09	1.82	27	-13	-13	-27	-10
Debt-free Net Working Capital (DFNWC)	0.00	224	422	525	1,822	919	998	1,141	830
Net Working Capital (NWC)	0.00	223	422	525	1,822	919	998	1,141	830
Net Nonoperating Expense (NNE)	15	30	19	10	68	97	274	84	126
Net Nonoperating Obligations (NNO)	0.00	-294	-497	-792	-1,235	-496	126	-29	303
Total Depreciation and Amortization (D&A)	3.98	5.57	6.72	9.10	25	38	43	32	38
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	4.39%	3.40%	0.85%	9.30%	-3.56%	-2.86%	-4.87%	-1.41%
Debt-free Net Working Capital to Revenue	0.00%	448.43%	465.64%	244.72%	635.28%	246.07%	222.09%	202.36%	112.25%
Net Working Capital to Revenue	0.00%	448.03%	465.64%	244.72%	635.28%	246.07%	222.09%	202.36%	112.25%
Earnings Adjustments	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($3.53)	($7.07)	($2.80)	($0.84)	($2.60)	($4.00)	($6.41)	($4.28)	($3.56)
Adjusted Weighted Average Basic Shares Outstanding	13.05M	12.58M	85.93M	94.38M	100.43M	101.31M	102.18M	111.99M	122.75M
Adjusted Diluted Earnings per Share	($3.53)	($7.07)	($2.80)	($0.84)	($2.60)	($4.00)	($6.41)	($4.28)	($3.56)
Adjusted Weighted Average Diluted Shares Outstanding	13.05M	12.58M	85.93M	94.38M	100.43M	101.31M	102.18M	111.99M	122.75M
Adjusted Basic & Diluted Earnings per Share	($3.53)	($7.07)	($2.80)	($0.84)	($2.60)	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	13.05M	12.58M	30.40M	90.60M	97.50M	101.87M	102.66M	121.71M	123.42M
Normalized Net Operating Profit after Tax (NOPAT)	-31	-54	-65	-58	-178	-288	-381	-395	-311
Normalized NOPAT Margin	-121.56%	-107.60%	-71.78%	-26.90%	-62.24%	-77.00%	-84.77%	-70.10%	-42.02%
Pre Tax Income Margin	-182.71%	-166.96%	-92.92%	-32.52%	-85.76%	-102.89%	-145.36%	-84.90%	-58.87%
Debt Service Ratios	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-14.53	-9.99	-70.54	-69.67	-52.73	-149.72	-5.58	0.00	0.00
NOPAT to Interest Expense	-10.17	-6.90	-52.01	-48.82	-37.45	-111.64	-3.82	0.00	0.00
EBIT Less CapEx to Interest Expense	-15.11	-10.85	-86.69	-85.52	-60.32	-178.84	-6.36	0.00	0.00
NOPAT Less CapEx to Interest Expense	-10.76	-7.75	-68.16	-64.67	-45.04	-140.76	-4.60	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-0.22%	-8.68%	-5.41%	-1.07%	-0.46%	0.00%	0.00%	-4.41%	0.00%

This table displays calculated financial ratios and metrics derived from Guardant Health's official financial filings.

Metric	Q3 2022	Q4 2022	Q1 2023	Q2 2023	Q3 2023	Q4 2023	Q1 2024	Q2 2024	Q3 2024	Q4 2024
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	23.87%	17.37%	33.94%	25.66%	21.83%	22.19%	30.90%	29.23%	33.87%	30.16%
EBITDA Growth	-55.66%	-106.82%	-11.17%	41.96%	39.33%	-49.04%	6.68%	-51.10%	-20.70%	40.53%
EBIT Growth	-51.65%	-94.77%	-9.99%	39.70%	40.70%	-42.59%	5.09%	-47.74%	-24.50%	39.60%
NOPAT Growth	-34.78%	-48.79%	-8.69%	8.21%	21.48%	-35.17%	25.64%	15.88%	-3.33%	36.22%
Net Income Growth	-50.66%	-93.52%	-8.36%	68.28%	46.85%	-33.67%	13.89%	-41.03%	-25.15%	40.65%
EPS Growth	-49.06%	-53.93%	-7.44%	70.22%	53.80%	-15.33%	27.69%	-25.37%	-20.55%	43.04%
Operating Cash Flow Growth	-47.07%	-17.87%	-160.11%	16.01%	0.47%	13.25%	59.32%	0.01%	34.36%	18.06%
Free Cash Flow Firm Growth	22.12%	-43.34%	70.25%	59.50%	15.89%	41.30%	112.92%	144.45%	146.28%	-47.78%
Invested Capital Growth	13.14%	25.02%	-20.08%	-5.65%	12.76%	-30.23%	-49.10%	-49.45%	-61.12%	25.31%
Revenue Q/Q Growth	7.57%	8.08%	1.44%	6.55%	4.29%	8.41%	8.67%	5.19%	8.04%	5.40%
EBITDA Q/Q Growth	-28.37%	15.80%	2.38%	44.99%	-34.19%	-106.84%	38.87%	10.94%	-7.19%	-1.91%
EBIT Q/Q Growth	-25.43%	13.59%	3.64%	42.26%	-23.36%	-107.77%	35.86%	10.12%	-3.95%	-0.80%
NOPAT Q/Q Growth	-10.96%	-1.05%	8.26%	10.77%	5.08%	-73.95%	49.53%	-0.94%	-16.61%	-7.36%
Net Income Q/Q Growth	29.39%	13.62%	4.57%	45.50%	-18.32%	-117.23%	38.52%	10.75%	-4.99%	-3.02%
EPS Q/Q Growth	29.78%	13.29%	5.11%	48.46%	-8.96%	-116.44%	40.51%	10.64%	-4.76%	-2.27%
Operating Cash Flow Q/Q Growth	30.17%	-16.11%	17.97%	-26.29%	17.26%	-1.20%	61.53%	-210.40%	45.68%	-26.35%
Free Cash Flow Firm Q/Q Growth	30.11%	-13.36%	60.94%	-30.89%	-45.13%	20.89%	108.60%	350.17%	51.12%	-352.60%
Invested Capital Q/Q Growth	-13.80%	-1.26%	-16.03%	32.02%	3.02%	-38.90%	-38.75%	31.10%	-20.75%	96.92%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	99.10%	97.31%	93.81%	96.73%	97.23%	96.71%	96.44%	96.22%	95.62%	95.97%
EBITDA Margin	-130.30%	-101.50%	-97.68%	-50.43%	-64.89%	-123.80%	-69.64%	-58.96%	-58.50%	-56.57%
Operating Margin	-123.16%	-115.15%	-104.15%	-87.22%	-79.38%	-127.38%	-59.16%	-56.77%	-61.28%	-62.42%
EBIT Margin	-138.83%	-110.99%	-105.43%	-57.13%	-67.58%	-129.52%	-76.45%	-65.32%	-62.85%	-60.10%
Profit (Net Income) Margin	-137.98%	-110.28%	-103.74%	-53.06%	-60.20%	-120.63%	-68.24%	-57.91%	-56.28%	-55.00%
Tax Burden Percent	100.07%	100.43%	100.18%	100.69%	100.57%	99.71%	100.35%	100.13%	100.03%	100.65%
Interest Burden Percent	99.32%	98.93%	98.22%	92.24%	88.57%	93.41%	88.96%	88.54%	89.52%	90.92%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-208.92%	-216.09%	-199.58%	-146.40%	-148.30%	-317.91%	-211.79%	-164.55%	-200.94%	-220.45%
ROIC Less NNEP Spread (ROIC-NNEP)	-187.97%	-195.72%	-141.31%	-158.17%	-352.97%	-417.99%	-254.37%	-489.01%	-241.19%	-237.12%
Return on Net Nonoperating Assets (RNNOA)	116.54%	102.64%	39.41%	48.17%	-5.78%	-186.19%	-2,276.04%	-33.34%	-182.59%	-3,411.61%
Return on Equity (ROE)	-92.38%	-113.45%	-160.17%	-98.23%	-154.08%	-504.10%	-2,487.83%	-197.89%	-383.53%	-3,632.06%
Cash Return on Invested Capital (CROIC)	-207.83%	-249.48%	-198.30%	-173.31%	-190.99%	-214.31%	-249.40%	-164.52%	-156.01%	-234.47%
Operating Return on Assets (OROA)	-30.45%	-26.16%	-27.92%	-15.78%	-20.70%	-43.01%	-28.70%	-24.38%	-26.08%	-27.15%
Return on Assets (ROA)	-30.27%	-25.99%	-27.47%	-14.66%	-18.44%	-40.06%	-25.62%	-21.62%	-23.36%	-24.85%
Return on Common Equity (ROCE)	-86.52%	-113.45%	-160.17%	-98.23%	-154.08%	-504.10%	-2,487.83%	-197.89%	-383.53%	-3,632.06%
Return on Equity Simple (ROE_SIMPLE)	-352.01%	0.00%	1,492.43%	-173.62%	-189.37%	0.00%	-674.97%	0.00%	852.65%	0.00%
Net Operating Profit after Tax (NOPAT)	-101	-102	-94	-84	-79	-138	-70	-70	-82	-88
NOPAT Margin	-86.22%	-80.61%	-72.90%	-61.05%	-55.57%	-89.17%	-41.41%	-39.74%	-42.89%	-43.69%
Net Nonoperating Expense Percent (NNEP)	-20.95%	-20.36%	-58.27%	11.76%	204.66%	100.08%	42.57%	324.45%	40.25%	16.67%
Return On Investment Capital (ROIC_SIMPLE)	-	-8.54%	-	-	-	-10.65%	-	-	-	-8.79%
Cost of Revenue to Revenue	0.90%	2.69%	6.19%	3.27%	2.77%	3.29%	3.56%	3.78%	4.38%	4.03%
SG&A Expenses to Revenue	35.03%	29.86%	31.42%	30.27%	25.29%	78.08%	22.94%	22.83%	25.66%	25.71%
R&D to Revenue	85.19%	83.99%	72.35%	65.88%	65.62%	57.95%	49.74%	46.89%	45.60%	46.35%
Operating Expenses to Revenue	222.26%	212.46%	197.96%	183.94%	176.61%	224.09%	155.61%	152.99%	156.89%	158.39%
Earnings before Interest and Taxes (EBIT)	-163	-141	-136	-78	-97	-201	-129	-116	-120	-121
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-153	-129	-126	-69	-93	-192	-117	-104	-112	-114
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	33.00	46.30	0.00	12.57	15.28	20.11	35.65	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	36.43	61.69	0.00	13.18	16.20	21.80	42.93	0.00	0.00	0.00
Price to Revenue (P/Rev)	12.77	6.20	4.99	7.21	6.51	5.66	4.03	5.49	4.08	5.11
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	29.27	15.63	16.67	17.39	16.32	24.33	30.71	34.86	35.84	25.03
Enterprise Value to Revenue (EV/Rev)	12.83	6.48	5.41	7.04	6.48	5.61	4.05	5.65	4.28	5.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	6.82	18.90	-25.54	3.89	4.99	7.18	16.70	-707.54	-19.00	-8.18
Long-Term Debt to Equity	6.82	18.90	-25.54	3.89	4.99	7.18	16.70	-707.54	-19.00	-8.18
Financial Leverage	-0.62	-0.52	-0.28	-0.30	0.02	0.45	8.95	0.07	0.76	14.39
Leverage Ratio	4.20	5.41	7.45	6.04	8.86	15.52	135.51	11.85	19.83	171.88
Compound Leverage Factor	4.17	5.35	7.32	5.57	7.85	14.50	120.55	10.49	17.75	156.28
Debt to Total Capital	87.21%	94.97%	104.07%	79.55%	83.31%	87.78%	94.35%	100.14%	105.56%	113.92%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	87.21%	94.97%	104.07%	79.55%	83.31%	87.78%	94.35%	100.14%	105.56%	113.92%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	12.79%	5.03%	-4.07%	20.45%	16.69%	12.22%	5.65%	-0.14%	-5.56%	-13.92%
Debt to EBITDA	-2.54	-2.21	-2.16	-2.39	-2.74	-2.38	-2.42	-2.25	-2.17	-2.55
Net Debt to EBITDA	-0.05	-0.25	-0.38	0.18	0.04	0.06	-0.02	-0.21	-0.27	-0.68
Long-Term Debt to EBITDA	-2.54	-2.21	-2.16	-2.39	-2.74	-2.38	-2.42	-2.25	-2.17	-2.55
Debt to NOPAT	-3.27	-2.98	-2.93	-2.99	-3.17	-2.88	-3.07	-3.19	-3.17	-3.68
Net Debt to NOPAT	-0.06	-0.33	-0.52	0.23	0.04	0.07	-0.03	-0.30	-0.40	-0.97
Long-Term Debt to NOPAT	-3.27	-2.98	-2.93	-2.99	-3.17	-2.88	-3.07	-3.19	-3.17	-3.68
Altman Z-Score	1.51	0.37	0.00	0.92	0.68	0.21	-0.09	0.24	-0.19	-0.14
Noncontrolling Interest Sharing Ratio	6.35%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.46	6.17	5.41	6.96	5.94	6.54	5.95	6.40	6.22	4.68
Quick Ratio	5.96	5.74	5.02	6.53	5.48	6.11	5.52	5.63	5.51	4.21
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-123	-140	-55	-71	-104	-82	7.05	32	48	-121
Operating Cash Flow to CapEx	-359.75%	-907.40%	-989.38%	-1,443.50%	-3,279.55%	-1,931.03%	-436.75%	-1,851.53%	-1,215.98%	-341.79%
Free Cash Flow to Firm to Interest Expense	-191.20	0.00	-84.65	0.00	0.00	0.00	10.92	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	-121.37	0.00	-115.59	0.00	0.00	0.00	-46.95	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	-155.10	0.00	-127.27	0.00	0.00	0.00	-57.70	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.22	0.24	0.26	0.28	0.31	0.33	0.38	0.37	0.42	0.45
Accounts Receivable Turnover	5.86	4.61	5.62	5.61	6.12	6.06	7.03	6.89	7.81	7.43
Inventory Turnover	0.13	0.20	0.36	0.28	0.28	0.38	0.36	0.34	0.35	0.44
Fixed Asset Turnover	3.14	3.08	3.07	3.20	3.39	3.60	4.00	4.47	5.07	5.24
Accounts Payable Turnover	0.21	0.06	0.13	0.15	0.16	0.19	0.17	0.19	0.24	0.65
Days Sales Outstanding (DSO)	62.26	79.13	64.93	65.02	59.61	60.20	51.92	53.01	46.73	49.15
Days Inventory Outstanding (DIO)	2,725.11	1,847.73	1,024.83	1,297.70	1,288.63	962.75	1,022.02	1,069.35	1,040.61	830.93
Days Payable Outstanding (DPO)	1,756.55	6,314.91	2,747.66	2,431.90	2,264.60	1,929.44	2,129.99	1,938.41	1,538.18	563.98
Cash Conversion Cycle (CCC)	1,030.82	-4,388.06	-1,657.91	-1,069.19	-916.36	-906.49	-1,056.05	-816.05	-450.84	316.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	189	186	156	207	213	130	80	104	83	163
Invested Capital Turnover	2.42	2.68	2.74	2.40	2.67	3.57	5.11	4.14	4.68	5.05
Increase / (Decrease) in Invested Capital	22	37	-39	-12	24	-56	-77	-102	-130	33
Enterprise Value (EV)	5,524	2,912	2,607	3,593	3,473	3,163	2,446	3,640	2,965	4,077
Market Capitalization	5,503	2,786	2,406	3,679	3,488	3,192	2,434	3,534	2,822	3,775
Book Value per Share	$1.63	$0.59	($0.43)	$2.85	$1.94	$1.34	$0.56	($0.01)	($0.49)	($1.13)
Tangible Book Value per Share	$1.48	$0.44	($0.57)	$2.72	$1.83	$1.24	$0.47	($0.10)	($0.57)	($1.21)
Total Capital	1,303	1,198	1,093	1,431	1,368	1,299	1,209	1,140	1,082	1,003
Total Debt	1,137	1,137	1,138	1,139	1,139	1,140	1,141	1,141	1,142	1,143
Total Long-Term Debt	1,137	1,137	1,138	1,139	1,139	1,140	1,141	1,141	1,142	1,143
Net Debt	22	126	201	-86	-15	-29	11	106	143	303
Capital Expenditures (CapEx)	22	10	7.52	6.51	2.37	4.08	6.93	5.08	4.20	19
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-2.31	-13	-37	-28	-35	-27	-41	53	30	-10
Debt-free Net Working Capital (DFNWC)	956	998	900	1,197	1,120	1,141	1,089	1,088	1,029	830
Net Working Capital (NWC)	956	998	900	1,197	1,120	1,141	1,089	1,088	1,029	830
Net Nonoperating Expense (NNE)	61	38	40	-11	6.62	49	45	32	26	23
Net Nonoperating Obligations (NNO)	22	126	201	-86	-15	-29	11	106	143	303
Total Depreciation and Amortization (D&A)	10	12	9.98	9.20	3.85	8.87	11	11	8.32	7.14
Debt-free, Cash-free Net Working Capital to Revenue	-0.54%	-2.86%	-7.61%	-5.51%	-6.47%	-4.87%	-6.74%	8.26%	4.38%	-1.41%
Debt-free Net Working Capital to Revenue	221.87%	222.09%	186.73%	234.58%	209.07%	202.36%	180.30%	169.06%	148.70%	112.25%
Net Working Capital to Revenue	221.87%	222.09%	186.73%	234.58%	209.07%	202.36%	180.30%	169.06%	148.70%	112.25%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($1.58)	($1.37)	($1.30)	($0.67)	($0.73)	($1.58)	($0.94)	($0.84)	($0.88)	($0.90)
Adjusted Weighted Average Basic Shares Outstanding	102.29M	102.18M	102.66M	108.81M	117.74M	111.99M	121.71M	122.45M	123.05M	122.75M
Adjusted Diluted Earnings per Share	($1.58)	($1.37)	($1.30)	($0.67)	($0.73)	($1.58)	($0.94)	($0.84)	($0.88)	($0.90)
Adjusted Weighted Average Diluted Shares Outstanding	102.29M	102.18M	102.66M	108.81M	117.74M	111.99M	121.71M	122.45M	123.05M	122.75M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	102.44M	102.66M	102.76M	117.69M	117.99M	121.71M	122.37M	123.02M	123.55M	123.42M
Normalized Net Operating Profit after Tax (NOPAT)	-101	-102	-94	-84	-79	-138	-70	-70	-82	-88
Normalized NOPAT Margin	-86.22%	-80.61%	-72.90%	-61.05%	-55.57%	-89.17%	-41.41%	-39.74%	-42.89%	-43.69%
Pre Tax Income Margin	-137.88%	-109.80%	-103.56%	-52.70%	-59.86%	-120.98%	-68.00%	-57.83%	-56.26%	-54.65%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	-253.09	0.00	-210.73	0.00	0.00	0.00	-199.69	0.00	0.00	0.00
NOPAT to Interest Expense	-157.17	0.00	-145.71	0.00	0.00	0.00	-108.18	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	-286.82	0.00	-222.41	0.00	0.00	0.00	-210.45	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	-190.91	0.00	-157.40	0.00	0.00	0.00	-118.93	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	-4.19%	-4.74%	-4.41%	0.00%	0.03%	-0.13%	0.00%

Frequently Asked Questions About Guardant Health's Financials

When does Guardant Health's fiscal year end?

According to the most recent income statement we have on file, Guardant Health's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Guardant Health's net income changed over the last 8 years?

Guardant Health's net income appears to be on an upward trend, with a most recent value of -$436.37 million in 2024, rising from -$46.14 million in 2016. The previous period was -$479.45 million in 2023.

What is Guardant Health's operating income?

Guardant Health's total operating income in 2024 was -$443.59 million, based on the following breakdown:

Total Gross Profit: $709.80 million
Total Operating Expenses: $1.15 billion

How has Guardant Health revenue changed over the last 8 years?

Over the last 8 years, Guardant Health's total revenue changed from $25.25 million in 2016 to $739.02 million in 2024, a change of 2,826.9%.

How much debt does Guardant Health have?

Guardant Health's total liabilities were at $1.63 billion at the end of 2024, a 0.2% decrease from 2023, and a 4,633.9% increase since 2017.

How much cash does Guardant Health have?

In the past 7 years, Guardant Health's cash and equivalents has ranged from $72.28 million in 2017 to $1.13 billion in 2023, and is currently $525.54 million as of their latest financial filing in 2024.

How has Guardant Health's book value per share changed over the last 8 years?

Over the last 8 years, Guardant Health's book value per share changed from 0.00 in 2016 to -1.13 in 2024, a change of -113.0%.

Remove Ads

Related Companies

This page (NASDAQ:GH) was last updated on 4/15/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Guardant Health (GH) Financials

Frequently Asked Questions About Guardant Health's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Guardant Health (GH) Financials

Annual Income Statements for Guardant Health

Quarterly Income Statements for Guardant Health

Annual Cash Flow Statements for Guardant Health

Quarterly Cash Flow Statements for Guardant Health

Annual Balance Sheets for Guardant Health

Quarterly Balance Sheets for Guardant Health

Annual Metrics and Ratios for Guardant Health

Quarterly Metrics and Ratios for Guardant Health

Frequently Asked Questions About Guardant Health's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools